Spontaneous intracerebral hemorrhage and delayed cerebral vasospasm in a patient with COVID-19 Infection by Sommer, Björn et al.
Arch Neurosci. 2021 July; 8(3):e116184.
Published online 2021 August 21.
doi: 10.5812/ans.116184.
Case Report
Spontaneous Intracerebral Hemorrhage and Delayed Cerebral
Vasospasm in a Patient with COVID-19 Infection
Björn Sommer 1, *, Christoph Maurer 2, Ansgar Berlis 2 and Ehab Shiban 1
1Department of Neurosurgery, University Hospital Augsburg, Augsburg, Germany
2Department of Neuroradiology, University Hospital Augsburg, Augsburg, Germany
*Corresponding author: Department of Neurosurgery, University Hospital Augsburg, Augsburg, Germany. Email: bjoern.sommer@uk-augsburg.de
Received 2021 May 17; Revised 2021 August 06; Accepted 2021 August 09.
Abstract
Introduction: The SARS-CoV-2 may cause vasculitis and thromboembolic events. We report on an unusual case of spontaneous
intracerebral hemorrhage and delayed cerebral vasospasms in a patient with COVID-19.
Case Presentation: A 65-year-old male was transferred to the emergency department due to a short period of unconsciousness.
Twenty-two hours prior to presentation, the patient had a 39.5°C fever with breathing difficulties. Initial COVID-19 PCR was positive.
While conscious and without any neurological impairment, a large right frontal intracerebral hemorrhage (ICH) was detected. A
preoperative angiogram showed no pathological blood vessels or vasospasm. The patients had a generalized tonic-clonic seizure
due to ICH progression, which led to an immediate microsurgical ICH removal. Thirteen days thereafter, the patient became uncon-
scious again. Angiography revealed severe cerebral vasospasm (CV) that required repetitive percutaneous transluminal angioplasty
(PTA) and intra-arterial nimodipine treatment.
Conclusions: We present the first case of ICH and delayed vasospasm associated with COVID-19. In these patients, combined maxi-
mum surgical and endovascular therapy is needed.
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1. Introduction
The global pandemic caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is om-
nipresent. The pathological cellular mechanisms that in-
duce a cytokine release “storm” are believed to go through
different phases, which lead to dysregulation of the im-
mune system (1). As the angiotensin-converting-enzyme 2
(ACE2) receptor is a co-receptor for virus spike proteins, it
might inflict indirect damage of the cerebrovascular en-
dothelium cells due to an interaction of the viral “S” pro-
tein and the ACE2 receptor, leading to inflammation and
apoptosis (2). Another mechanism of the pathophysiol-
ogy of ICH in COVID-19 patients could be the direct inter-
action of the virus with the endothelium causing rupture
of capillaries with subsequent intracerebral hemorrhage.
The breakdown of the blood-brain barrier is also induced
by pro-inflammatory cytokines, alterations in the coagu-
lation cascade, and complement system. The risk of ICH
could also be increased by an accumulation of angiotensin
II in the local endothelium due to a downregulation of
the ACE2 receptor by SARS-CoV-2, which then interacts with
the renin-angiotensin-aldosterone system (3, 4). In this re-
port, we present a rare case of ICH with delayed cerebral
vasospasm (CV).
2. Case Presentation
A 65-year-old male suddenly became unconscious
while drinking alcoholic beverages. He celebrated a birth-
day with five families the day before, had a 39.5°C fever but
did not follow the rules of social distancing. In his past
medical history, he had a sick-sinus syndrome requiring
a cardiac pacemaker and a 40 pack-year history. On the
day of admission, the blood serum alcohol level was 4.3
g/L. He had no fever or neurological deficits, no cough, and
only dyspnoea under physical load. Chest X-ray showed
a density of the left basolateral lung without inflamma-
tory reactions. SARS-Corona PCR (Cepheid and Hologic)
was positive. D-Dimer was elevated with 9,696 ng/mL, in-
flammatory parameters were as follow: CRP 5.08 mg/dL, IL-
6 95.1 pg/mL, and Thrombocyte count was 81/nL. Shortly af-
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ter admission, he suffered from a generalized tonic-clonic
seizure. CT-scan showed a space-occupying right frontal
intracerebral hemorrhage (ICH) and concomitant subdu-
ral hematoma (Figure 1). CT-angiography (CT-A) and cere-
bral angiography (DSA) failed to show any vascular abnor-
malities. A high-resolution CT of the chest showed no fea-
tures of COVID-19. Cranial CT follow-up revealed a pro-
gression of the ICH, which led to an immediate micro-
surgical evacuation. The postoperative period was unre-
markable. Thirteen days following surgery, the patient be-
came unconscious again. CT-A revealed severe cerebral va-
sospasm of the right MCA, both ACA and basilar artery re-
quiring repetitive PTAs and intra-arterial nimodipine as
well as oral nimodipine treatment regimes. After four
days, vasospasm eventually resolved. Due to a malresorp-
tive hydrocephalus, a ventriculoperiotoneal shunt was im-
planted on day 26 after the occurrence of the ICH. Final
CT revealed infarction in the right posterior MCA territory
(Figure 1). The patient was transferred to a rehabilitation
center with a modified Rankin Scale score of 4.
3. Discussion
We report, to our knowledge, the first case of ICH with
delayed severe cerebral vasospasms in a COVID-19. Neu-
rovascular injuries after SARS-CoV-2 infection are one of
the important manifestations, with a reported stroke in-
cidence of 1 - 2% of all COVID-19 hospitalized patients (5).
The relationship between spontaneous intracerebral hem-
orrhage and the SARS-CoV-2 infection remains unclear. A
recent European multicenter study reported on 18 patients
with acute intracranial hemorrhage. Although a direct as-
sociation between the infection could not be proven, they
concluded it might be more likely in patients with severe
symptoms of COVID-19 (6). This is in line with previous re-
ports that critically ill patients are prone to cerebrovascu-
lar complications (7). Our patient, however, had mild respi-
ratory symptoms and was intubated due to his neurologi-
cal deterioration. It is not clear whether a direct viral infec-
tion or an indirect pathomechanism such as an inflamma-
tory reaction, dysfunction of the coagulation pathway, or
an autoimmune mechanism causes cerebrovascular dam-
age. There are at least three possible mechanisms respon-
sible for the development of CV in COVID-19 patients. First,
the ICH itself can induce CV due to CSF heme products that
induce oxidative stress and inflammation (8, 9). Second,
vasculitis is seen in cerebral vessels of patients with SARS-
CoV-2, which can explain endothelial damage and vaso-
constriction leading to CV (10). Third, a reversible vaso-
constriction syndrome (RCVS) of cerebral arteries has been
described (11, 12). Another patient succumbed to a dev-
astating diffuse arterial and dural venous sinus construc-
tion with generalized cerebral edema four days after ad-
mission (13). It was hypothesized that SARS-CoV-2 might in-
duce vasoconstriction due to downregulation of the ACE2
receptor, which then provoked an over activation of the
renin-angiotensin-aldosterone axis. In non-COVID-19 pa-
tients, the RCVS can cause ICH in about 34 - 43% of cases,
possibly due to a failure in cerebral autoregulation with
reperfusion injury-causing rupture of cortical blood ves-
sels (11, 14). In our patient, we suspect a strong association
between the occurrence of the COVID-19, spontaneous ICH,
and subsequent CV; however, the hypothesis of a direct in-
teraction of the virus crossing the blood-brain barrier can-
not be proven in our patient. The analysis of the CSF re-
vealed no specific SARS-CoV-2-virus RNA in our patient. This
finding does not exclude the suggested pathomechanism
and is in accordance with other case reports (15).
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Figure 1. A, initial cCT depicts right frontal ICH with subdural hematoma; B, in the course of hospital stay, cerebral vasospasm occurred on the 13th postoperative day (an-
giogram p.a.-projection of right ICA injection); C, after four times of PTA and local spasmolysis, vasospams of the ACA and MCA-territories resolved; D, final cCT after vp-shunt
implantation revealed partial infarction of the right posterior MCA-territory.
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